<DOC>
	<DOC>NCT00850239</DOC>
	<brief_summary>The purpose of this study is to demonstrate the efficacy of dutogliptin over 26 weeks (as evidenced by placebo-corrected changes in HbA1c relative to baseline), to demonstrate safety and tolerability of dutogliptin, and to demonstrate changes in fasting plasma glucose over 26 weeks.</brief_summary>
	<brief_title>Safety and Efficacy Study of Dutogliptin/PHX1149T in Subjects With Type 2 Diabetes Mellitus on a Background Medication of Metformin</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Type 2 diabetes mellitus, diagnosed at least 4 months prior to Screening (Visit 1) Age 18 to 85 years, inclusive. Male and nonpregnant, nonlactating (and not planning to become pregnant during the study) female subjects with a BMI of 20 to 48 kg/m2, inclusive Current treatment of Type 2 diabetes mellitus with a stable dose of metformin of â‰¥ 2000 mg (or the highest tolerated dose) used in accordance with product labeling for at least 6 weeks prior to screening (Visit 1) HbA1c 7.0% 10.0%, inclusive; and fasting plasma C peptide greater than 0.26 nmol/L (&gt; 0.8 ng/mL; &gt; 281 pmol/L) at screening (Visit 1) Type 1 diabetes mellitus</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>August 2010</verification_date>
	<keyword>diabetes</keyword>
	<keyword>DPP4 inhibitor</keyword>
	<keyword>dutogliptin</keyword>
</DOC>